{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:05:02Z","timestamp":1784016302780,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nano.2026.102980","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:54:16Z","timestamp":1781625256000},"page":"102980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Spatiotemporally controlled depletion of efflux-dominant cells enhances intratumoral delivery of nanomedicines"],"prefix":"10.1016","volume":"75","author":[{"given":"Chengqiong","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2026.102980_bb0005","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1042\/BST20210343","article-title":"Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface","volume":"49","author":"Tracey","year":"2021","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.nano.2026.102980_bb0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.nano.2026.102980_bb0015","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2026.102980_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2026.102980_bb0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102980_bb0030","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.7150\/thno.38625","article-title":"Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment","volume":"10","author":"de Maar","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2026.102980_bb0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2026.102980_bb0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41419-024-06949-3","article-title":"Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer","volume":"15","author":"Sarwar","year":"2024","journal-title":"Cell Death Dis"},{"issue":"14","key":"10.1016\/j.nano.2026.102980_bb0045","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1111\/febs.17135","article-title":"ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer","volume":"291","author":"Chen","year":"2024","journal-title":"FEBS J"},{"key":"10.1016\/j.nano.2026.102980_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010666","article-title":"Comprehensive evaluation of multiple approaches targeting ABCB1 to resensitize docetaxel-resistant prostate cancer cell lines","volume":"24","author":"Linke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102980_bb0055","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3892\/ol.2017.5986","article-title":"Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells","volume":"13","author":"Vallo","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.nano.2026.102980_bb0060","article-title":"Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2026.102980_bb0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a better understanding of the complexity of cancer drug resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nano.2026.102980_bb0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17460441.2022.2112666","article-title":"Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery","volume":"17","author":"Feyzizadeh","year":"2022","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1016\/j.nano.2026.102980_bb0075","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2026.102980_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/nn305011p","article-title":"Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors","volume":"7","author":"Sano","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2026.102980_bb0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/pros.20581","article-title":"The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines","volume":"67","author":"Takeda","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.nano.2026.102980_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1208\/s12249-013-0041-3","article-title":"Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy","volume":"15","author":"Ding","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.nano.2026.102980_bb0095","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/mp300472y","article-title":"Evaluation of the near infrared compound indocyanine green as a probe substrate of p-glycoprotein","volume":"9","author":"Portnoy","year":"2012","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.nano.2026.102980_bb0100","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-infrared photoimmunotherapy of cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.nano.2026.102980_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.980239","article-title":"Photodynamic therapy for prostate cancer: recent advances, challenges and opportunities","volume":"12","author":"Xue","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2026.102980_bb0110","first-page":"116","article-title":"Focal therapy for prostate cancer: recent advances and future directions","volume":"18","author":"Wang","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.nano.2026.102980_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215117","article-title":"Review of RM-1929 near-infrared photoimmunotherapy clinical efficacy for unresectable and\/or recurrent head and neck squamous cell carcinoma","volume":"15","author":"Miyazaki","year":"2023","journal-title":"Cancers"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996342600081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996342600081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:26:54Z","timestamp":1784014014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154996342600081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S154996342600081X"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102980","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatiotemporally controlled depletion of efflux-dominant cells enhances intratumoral delivery of nanomedicines","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102980"}}